Âé¶¹ÆÆ½â°æ featured in Biomim’BOOK 2021
Âé¶¹ÆÆ½â°æ is featured in the 2021 edition of Biomim’BOOK, the first book dedicated to actors and stakeholders in Biomimetism and Bio-inspiration.
To see the full book:
To see Âé¶¹ÆÆ½â°æ double page:
Read next in 'Latest news'
- Enrollment completed for our Phase 2 clinical trial in Alport syndrome
- The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
- The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH